June 23 (Reuters) - Japanese company Eisai Co and
partner Biogen Inc said on Wednesday the U.S. Food and
Drug Administration had granted breakthrough therapy designation
to their experimental therapy, lecanemab, for patients with
The drug works in a similar manner to Biogen's Aduhelm,
which was approved earlier this month. It removes sticky
deposits of a protein called amyloid beta from the brains of
patients in the earlier stages of Alzheimer's in order to stave
off its impact, including memory loss and the inability to take
care of oneself.
Eisai completed enrollment in March in a pivotal 18-month
study of lecanemab in symptomatic early Alzheimer's patients.
Lecanemab is also being studied in a large trial on people
with evidence of amyloid in their brains, who do not yet have
symptoms of the disease.
The FDA grants breakthrough therapy designation in order to
expedite the development and review of medicines for serious or
(Reporting by Dania Nadeem in Bengaluru;
Editing by Vinay Dwivedi)